The continuing evolution of the nation's blood supply system

American Journal of Clinical Pathology

Volumn 105, Issue 6, 1996, Pages 689-695

  Mccullough, Jeffrey ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Blood; Blood center; Blood supply

Indexed keywords

BLOOD BANK; BLOOD TRANSFUSION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; PRIORITY JOURNAL; REVIEW;

EID: 0029893236     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/105.6.689     Document Type: Review

References (50)

1. McCullough J. The nation's changing blood supply system. JAMA 1993;269:2239-2245.
2. Leveton LB, Sox HC, Stoto MA, eds. HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. Committee to Study HIV Transmission Through Blood and Blood Products: Division of Health Promotion and Disease Prevention, Institute of Medicine. Washington, DC: National Academy Press, 1995.
3. Solomon JM. The evolution of the current blood banking regulatory climate. Transfusion 1994;34:272-277.
4. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995;35:802-812.
5. Busch MP, Young MJ, Samson SJ, et al. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991;31:655-661.
6. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327: 369-373.
7. Blajchman MA, Bull SB, Feinman SV. Post-transfusion hepatitis: Impact of non-A, non-B hepatitis surrogate tests. Lancet 1995;345:21-25.
8. Holland PV. The effect of indirect markers of infectious disease on blood transfusion safety: Overview. National Institutes of Health Consensus Development Conference, January 9-11, 1995, Bethesda, Maryland, pp 17-20.
9. Kleinman S, Alter H, Busch P, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 1992;32:805-813.
10. Alter HJ. To C or not to C: These are the questions. Blood 1995;85: 1681-1695.
11. Alter HJ. Residual risk of transfusion-associated hepatitis. National Institutes of Health Consensus Development Conference, January 9-11, 1995, Bethesda, Maryland, p 23.
12. Lackritz EM, Satten GA, Aberle-Grasse J. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;26:1723-1725.
13. National Institutes of Health Consensus Development Conference Statement, Infectious Disease Testing for Blood Transfusions, January 9-11, 1995, Bethesda, Maryland.
14. Dodd RY. The risk of transfusion-transmitted infection. N Engl J Med 1992;327:419-421.
15. Hearings Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, 102nd Congress, 1st Session, April 18, 1991; May 15, 1991, (Blood Supply Safety).
16. Zuck TF. Current good manufacturing practices. Transfusion 1995;35:955-966.
17. Nevalainen DE, Callery MF. Quality Systems in the Blood Bank and Laboratory Environment. Abbott Quality Institute, Diagnostic Division, Abbott Laboratories, Abbott Park, Illinois., Bethesda, MD: American Association of Blood Banks, 1994.
18. Callery MF, Nevalainen DE, Kirst TM. Quality systems and total process control in blood banking. Transfusion 1994;34:899-906.
19. Guideline for Quality Assurance in Blood Establishments (Docket No. 91N-045). Food and Drug Administration, Rockville, Maryland, June 17, 1993.
20. Smith EN, Holland PV, Holliman SM, Fuller MJ. Staff costs associated with the implementation of a comprehensive compliance program in a community blood center. Transfusion 1995;35: 679-682.
21. Draft guideline for the validation of blood establishment computer systems (Docket No. 93N-0394). Center for Biologies Evaluation and Research, Food and Drug Administration, Rockville, Maryland, October 28, 1993.
22. Leape LL. Error in medicine. JAMA 1994;272:1851-1857.
23. Sayers MH. Duties to donors. Transfusion 1992;32:465-466.
24. Eschback JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989;11:992-1000.
25. Miller LL. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology 1993;7:67-78.
26. Aster RH. What makes platelets go? The cloning of thrombopoietin. Transfusion 1995;35:1-3.
27. McCullough J. The new generation of blood components (Editorial). Transfusion 1995;35:374-377.
28. Stroncek DF, Clay ME, Smith J, Ilstrup S, Oldham F, McCullough J. Changes in blood counts following the administration of G-CSF and the collection of peripheral blood stem cells from healthy donors. Transfusion (in press).
29. Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 1995;85:275-282.
30. Corringham RET, Ho AD. Rapid and sustained allogeneic transplantation using immunoselected CD34+-selected peripheral blood progenitor cells mobilized by recombinant granulocyte-and granulocyte-macrophage colony-stimulating factors. Blood 1995;86:2052-2054.
31. Russell NH, Hunter A, Rogers S, Hanley J, Anderson D. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993;341:1482.
32. Korbling M, Przepiorka D, Gajewski J, Champlin RE. With first successful allogeneic transplantations of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? Blood 1995;86:1235-1239.
33. Koller MR, Emerson SG, Palsson BO. Large-scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion cultures. Blood 1993;82: 378-384.
34. Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992;80:1405-1412.
35. Brugger W, Heimfeld S, Berenson RJ, et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995;333:283-287.
36. Henschler R, Brugger W, Luft T, Frey T, Mertelsmann R, Kanz L. Maintenance of transplantation potential in ex vivo expanded CD34+ -selected human peripheral blood progenitor cells. Blood 1994;84:2898-2903.
37. Wagner J, Kernan N, Steinbuch M, Broxmeyer H, Gluckman E. Allogneeic sibling umbilical-cord-blood tranplantation in children with malignant and non-malignant disease. Lancet 1995;346:214-219.
38. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
39. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-1268.
40. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994;83:3377-3383.
41. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
42. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;33:1038-1044.
43. Kessler DA, Siegel JP, Noguchi PD, Zoon KC, Feiden KL, Woodcock J. Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N Engl J Med 1993;329: 1169-1173.
44. McCullough J. Quality assurance and good manufacturing practices for processing hematopoietic progenitor cells. J Hematotherapy 1995;4:493-501.
45. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978;299:799-803.
46. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994;84;1703-1721.
47. Dodd RY. Scaling the heights. Transfusion 1995;35:186-188.
48. Conference on The Feasibility of Genetic Technology to Close the HIV Window in Donor Screening, Food and Drug Administration, September 26, 1994, Silver Spring, Maryland.
49. Piet MP, Chin S, Prince AM, et al. The use of tri-(n-butyl) phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 1990;30:591-598.
50. Vyas GN. Inactivation and removal of blood-born viruses (Editorial). Transfusion 1995;35:367-370.